Title:
CANCER DETECTION METHOD AND DETECTION REAGENT
Document Type and Number:
WIPO Patent Application WO/2020/218121
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a method for easily detecting cancer at a high accuracy and a reagent usable in this method. A method for detecting cancer (excluding renal cell cancer), said method comprising measuring the amount of azurocidin (AZU1) in a specimen, wherein when the measured value exceeds a preset standard value, then it is deemed that cancer is detected. Preferably, the cancer is selected from the group consisting of gastric cancer, breast cancer, bowel cancer and lung cancer. A reagent, which contains an antibody specifically recognizing AZU1, is used for detecting cancer (excluding renal cell cancer).
Inventors:
UEDA KOJI (JP)
OHNISHI NAOMI (JP)
TSUJIKAWA KAZUTAKE (JP)
NONOMURA NORIO (JP)
UEMURA MOTOHIDE (JP)
JINGUSHI KENTARO (JP)
OHTAKE NORIHISA (JP)
KAWAI YASUTOSHI (JP)
OHNISHI NAOMI (JP)
TSUJIKAWA KAZUTAKE (JP)
NONOMURA NORIO (JP)
UEMURA MOTOHIDE (JP)
JINGUSHI KENTARO (JP)
OHTAKE NORIHISA (JP)
KAWAI YASUTOSHI (JP)
Application Number:
PCT/JP2020/016607
Publication Date:
October 29, 2020
Filing Date:
April 15, 2020
Export Citation:
Assignee:
JAPANESE FOUND FOR CANCER RES (JP)
UNIV OSAKA (JP)
TOSOH CORP (JP)
UNIV OSAKA (JP)
TOSOH CORP (JP)
International Classes:
C07K14/47; C07K16/32; G01N33/574; G01N33/68
Domestic Patent References:
| WO2018217087A1 | 2018-11-29 | |||
| WO2018079689A1 | 2018-05-03 | |||
| WO2018079689A1 | 2018-05-03 | |||
| WO2016088689A1 | 2016-06-09 |
Foreign References:
| US20170153240A1 | 2017-06-01 | |||
| US20150141273A1 | 2015-05-21 | |||
| US20120077695A1 | 2012-03-29 | |||
| US20140045915A1 | 2014-02-13 | |||
| JP5166522B2 | 2013-03-21 | |||
| JP5488885B2 | 2014-05-14 | |||
| JPS5818916B2 | 1983-04-15 | |||
| JP2009240300A | 2009-10-22 |
Other References:
JINGUSHI, KENTARO ET AL.: "Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin", INTERNATIONAL JOURNAL OF CANCER, vol. 142, 2018, pages 607 - 617, XP055690699, DOI: 10.1002/ijc.31080
J LEUKOC BIOL, vol. 85, no. 3, March 2009 (2009-03-01), pages 344 - 51
TRENDS IMMUNOL, vol. 30, no. 11, November 2009 (2009-11-01), pages 547 - 56
NAT MED, vol. 7, no. 10, October 2001 (2001-10-01), pages 1123 - 7
THROMB HAEMOST, vol. 102, no. 2, August 2009 (2009-08-01), pages 198 - 205
INT J CANCER, vol. 142, no. 3, 1 February 2018 (2018-02-01), pages 607 - 617
See also references of EP 3960758A4
J LEUKOC BIOL, vol. 85, no. 3, March 2009 (2009-03-01), pages 344 - 51
TRENDS IMMUNOL, vol. 30, no. 11, November 2009 (2009-11-01), pages 547 - 56
NAT MED, vol. 7, no. 10, October 2001 (2001-10-01), pages 1123 - 7
THROMB HAEMOST, vol. 102, no. 2, August 2009 (2009-08-01), pages 198 - 205
INT J CANCER, vol. 142, no. 3, 1 February 2018 (2018-02-01), pages 607 - 617
See also references of EP 3960758A4
Attorney, Agent or Firm:
IP FIRM SHUWA (JP)
Download PDF: